An AAV Vector for Inducible Gene Expression Preferentially in Muscles

Open Access

Year : 2023 | Volume : 01 | Issue : 02 | Page : 46-61
By

    Renping Zhou

  1. Yicong Le,

  2. Zhengyun Jiang

  3. Xi Zheng,

  4. Christina Marinaro

  5. Suzie Chen,

  6. Bing Wang

  7. Suqing Zhao

  8. Min Chen

  9. Philip Furmanski

  10. Kun Zhang

  1. Associate Dean for Research, Professor, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854,, New Jersey, USA
  2. Researcher, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854,, , USA
  3. Reserarcher, School of Biomedical and Pharmaceutical Science, Guangdong University of Technology,, Guangzhou, China
  4. Researcher, Department Of Chemical Biology, Ernest Mario School Of Pharmacy, Rutgers, New Jersey, USA
  5. Researcher, Department Of Chemical Biology, Ernest Mario School Of Pharmacy, Rutgers, The State University Of New Jersey, Piscataway, NJ 08854,, New Jersey, USA
  6. Researcher, Department Of Chemical Biology, Ernest Mario School Of Pharmacy, Rutgers, The State University Of New Jersey, Piscataway, NJ 08854, USA; Rutgers Cancer Institute Of New Jersey, New Brunswick, NJ 08903,, New Jersey, USA
  7. Researcher, Department Of Medicine, University Of Pittsburgh, Pittsburgh, PA 15261,, Pittsburgh, USA
  8. Researcher, School Of Biomedical And Pharmaceutical Science, Guangdong University Of Technology, Guangzhou, China; School Of Biotechnology And Health Science, Wuyi University,, Jiangmen,, China
  9. Researcher, School Of Biomedical And Pharmaceutical Science, Guangdong University Of Technology, Guangzhou, China; School Of Biotechnology And Health Science, Wuyi University,, Jiangmen, China
  10. Researcher, Department Of Chemical Biology, Ernest Mario School Of Pharmacy, Rutgers, The State University Of New Jersey, Piscataway, NJ 08854, USA; Rutgers Cancer Institute Of New Jersey, New Brunswick, NJ 08903,, New Jersey, USA
  11. Researcher, School Of Biotechnology And Health Science, Wuyi University, Jiangmen, China

Abstract

Adeno associated viral (AAV) vectors has been used widely in gene therapy and efforts have been made to improve their utility by adding genetic elements that would enable targeting transgene expression to particular cells or tissues of interest and permitting on/off regulation of expression. In this study, we designed a recombinant AAV9 variant PHP.eB vector with muscle creatine kinase (Mck)-derived enhancers, a synthetic muscle-expression promoter, in combination with a third-generation tetracycline-inducible promoter, to drive expression of reporter genes luciferase and GFP (PHP.eB-Pmus-TetOn-teLuc and PHP.eB-Pmus-TetOn-eGFP, respectively). This recombinant vector expresses genes at high levels preferentially in muscle cells, that can be controlled by doxycycline (Dox) exposure both in vitro and in vivo. To test inducibility of these vectors in vivo, adult SKH hairless mice were injected intravenously with 2×1012 virus genomes. Dox-containing food (625 mg/kg) was given 1 day after virus injection to initiate expression. After one month, tissue luciferase activity was assayed. Luciferase expression level per viral genome in muscle tissues including biceps brachii, biceps femoris, and heart tissue were higher in Pmus-TetOn group. Long-term expression was also assessed for the PHP.eB-Pmus-TetOn-teLuc vector: two weeks after virus injection and Dox induction, Dox-containing food was replaced with conventional diet and luciferase expression was tracked biweekly using IVIS in vivo imaging. Following Dox removal, luciferase expression decreased and by 6 weeks had returned to basal levels. Re-exposure to Dox stimulated luciferase expression to levels similar to the first Dox-induced expression. Removal of the second Dox stimulus resulted in slow loss of luciferase activity, which could again be re-induced by Dox exposure. These experiments indicate that this inducible, tissue-selective expression could be maintained in vivo for at least 18 weeks.

Keywords: Gene therapy, AAV, muscle specific promoter, Tet-on, inducible gene expression

[This article belongs to International Journal of Genetic Modifications and Recombinations(ijgmr)]

How to cite this article: Renping Zhou, Yicong Le,, Zhengyun Jiang, Xi Zheng,, Christina Marinaro, Suzie Chen,, Bing Wang, Suqing Zhao, Min Chen, Philip Furmanski, Kun Zhang An AAV Vector for Inducible Gene Expression Preferentially in Muscles ijgmr 2023; 01:46-61
How to cite this URL: Renping Zhou, Yicong Le,, Zhengyun Jiang, Xi Zheng,, Christina Marinaro, Suzie Chen,, Bing Wang, Suqing Zhao, Min Chen, Philip Furmanski, Kun Zhang An AAV Vector for Inducible Gene Expression Preferentially in Muscles ijgmr 2023 {cited 2023 Dec 01};01:46-61. Available from: https://journals.stmjournals.com/ijgmr/article=2023/view=127970

Full Text PDF Download

Browse Figures

References

  1. Aguti, S.; Malerba, A.; Zhou, H. The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opin Biol Ther 2018, 18, 681-693.
  2. Chamberlain, J.R.; Chamberlain, J.S. Progress toward Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther 2017, 25, 1125-1131.
  3. Sudhakar, V.; Richardson, R.M. Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics 2019, 16, 166-175.
  4. Liang, F.Q.; Aleman, T.S.; Dejneka, N.S., et al. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 2001, 4, 461-472.
  5. Bok, D.; Yasumura, D.; Matthes, M.T. et al. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002, 74, 719-735.
  6. Schlichtenbrede, F.C.; MacNeil, A.; Bainbridge, J.W. et al. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther 2003, 10, 523-527.
  7. Georgievska, B.; Kirik, D.; Bjorklund, A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002, 177, 461-474.
  8. Hovland, D.N., Jr.; Boyd, R.B.; Butt, M.T, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 2007, 35, 1013-1029.
  9. Manfredsson, F.P.; Tumer, N.; Erdos, B., et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009, 17, 980-991.
  10. Su, X.; Kells, A.P.; Huang, E.J, et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009, 20, 1627-1640.
  11. Coulier, F.; Kumar, R.; Ernst, M, et al. Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol Cell Biol 1990, 10, 4202-4210.
  12. Yu, C.Y.; Yuan, Z.; Cao, Z., et al. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 2009, 16, 953-962.
  13. Challis, R.C.; Ravindra Kumar, S.; Chan, K.Y., et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc 2019, 14, 379-414.
  14. Yuasa, K.; Sakamoto, M.; Miyagoe-Suzuki, Y., et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther 2002, 9, 1576-1588.
  15. Stieger, K.; Le Meur, G.; Lasne, F., et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006, 13, 967-975.
  16. Vanrell, L.; Di Scala, M.; Blanco, L., et al. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther 2011, 19, 1245-1253.
  17. Dogbevia, G.K.; Robetamanith, M.; Sprengel, R., et al. Flexible, AAV-equipped Genetic Modules for Inducible Control of Gene Expression in Mammalian Brain. Mol Ther Nucleic Acids 2016, 5, e309.
  18. Sohn, J.; Takahashi, M.; Okamoto, S., et al. A Single Vector Platform for High-Level Gene Transduction of Central Neurons: Adeno-Associated Virus Vector Equipped with the Tet-Off System. PLoS One 2017, 12, e0169611.
  19. Reid, C.A.; Nettesheim, E.R.; Connor, T.B., et al. Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. Sci Rep 2018, 8, 11763.
  20. Monteys, A.M.; Hundley, A.A.; Ranum, P.T., et al. Regulated control of gene therapies by drug-induced splicing. Nature 2021, 596, 291-295.
  21. Chan, K.Y.; Jang, M.J.; Yoo, B.B., et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 2017, 20, 1172-1179.
  22. Xiong, W.; MacColl Garfinkel, A.E.; Li, Y., et al. NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. J Clin Invest 2015, 125, 1433-1445.
  23. Yeh, H.W.; Karmach, O.; Ji, A., et al. Red-shifted luciferase-luciferin pairs for enhanced bioluminescence imaging. Nat Methods 2017, 14, 971-974.
  24. Li, X.; Eastman, E.M.; Schwartz, R.J., et al. R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 1999, 17, 241-245.
  25. Lundstrom, K. Viral Vectors in Gene Therapy. Diseases 2018, 6.
  26. Cabanes-Creus, M.; Hallwirth, C.V.; Westhaus, A., et al. Restoring the natural tropism of AAV2 vectors for human liver. Sci Transl Med 2020, 12.
  27. Carneiro, A.; Lee, H.; Lin, L., e al. Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery. Hum Gene Ther 2020, 31, 996-1009.
  28. Charsar, B.A.; Brinton, M.A.; Locke, K., et al. AAV2-BDNF promotes respiratory axon plasticity and recovery of diaphragm function following spinal cord injury. FASEB J 2019, 33, 13775-13793.
  29. George, L.A.; Ragni, M.V.; Rasko, J.E.J., et al. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. Mol Ther 2020, 28, 2073-2082.
  30. Gross, S.K.; Shim, B.S.; Bartus, R.T., et al. N.J. Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. Exp Neurol 2020, 323, 113091.
  31. Qiao, C.; Zhang, W.; Yuan, Z., et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010, 21, 1343-1348.
  32. Riaz, M.; Raz, Y.; Moloney, E.B., et al. Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9. Skelet Muscle 2015, 5, 37.
  33. Pattali, R.; Mou, Y.; Li, X.J. AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther 2019, 26, 287-295.
  34. Saraiva, J.; Nobre, R.J.; Pereira de Almeida, L. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. J Control Release 2016, 241, 94-109.
  35. Zhou, X.; Vink, M.; Klaver, B., e al. Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther 2006, 13, 1382-1390.
  36. Hastie, E.; Samulski, R.J. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success–a personal perspective. Hum Gene Ther 2015, 26, 257-265.
  37. Wu, Z.; Asokan, A.; Samulski, R.J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006, 14, 316-327.
  38. Maguire, A.M.; Simonelli, F.; Pierce, E.A., et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008, 358, 2240-2248.
  39. Zincarelli, C.; Soltys, S.; Rengo, G., et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008, 16, 1073-1080.
  40. Gao, G.; Bish, L.T.; Sleeper, M.M., et al. Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques. Hum Gene Ther 2011, 22, 979-984.
  41. Ji, G.; Sun, S.; Wu, H., et al. Effect of AAV9-hIGF-1 on inflammatory reaction in mdx mice and its mechanism. Am J Transl Res 2020, 12, 4488-4497.
  42. Kolwicz, S.C., Jr.; Odom, G.L.; Nowakowski, S.G., et al. AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther 2016, 24, 240-250.
  43. Moulay, G.; Masurier, C.; Bigey, P., et al. Soluble TNF-alpha receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer. Gene Ther 2010, 17, 1400-1410.
  44. Hermiston, T.W.; Malone, C.L.; Witte, P.R., et al. Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter. J Virol 1987, 61, 3214-3221.
  45. Thomsen, D.R.; Stenberg, R.M.; Goins, W.F.et al. Promoter-regulatory region of the major immediate early gene of human cytomegalovirus. Proc Natl Acad Sci U S A 1984, 81, 659-663.
  46. Harms, J.S.; Splitter, G.A. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995, 6, 1291-1297.
  47. Hartigan-O’Connor, D.; Kirk, C.J.; Crawford, R., et al. J.S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001, 4, 525-533.
  48. Wang, B.; Li, J.; Fu, F.H., et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008, 15, 1489-1499.
  49. Sanftner, L.H.M.; Rendahl, K.G.; Quiroz, D., et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol Ther 2001, 3, 688-696.
  50. Chtarto, A.; Bender, H.U.; Hanemann, C.O., et al. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther 2003, 10, 84-94.
  51. Wang, J.J.; Zhang, T.; Niu, D.B., et al. Doxycycline-regulated co-expression of GDNF and TH in PC12 cells. Neurosci Lett 2006, 401, 142-145.
  52. Folliot, S.; Briot, D.; Conrath, H., et al. Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. J Gene Med 2003, 5, 493-501.
  53. Li, Z.B.; Zeng, Z.J.; Chen, Q., et al. W.X. Recombinant AAV-mediated HSVtk gene transfer with direct intratumoral injections and Tet-On regulation for implanted human breast cancer. BMC Cancer 2006, 6, 66.
  54. Ziegler, T.; Kraus, M.; Husada, W., et al. Steerable Induction of the Thymosin beta4/MRTF-A Pathway via AAV-Based Overexpression Induces Therapeutic Neovascularization. Hum Gene Ther 2017, 10.1089/hum.2017.013.
  55. Liu, Y.; Okada, T.; Shimazaki, K., et al. Protection Against Aminoglycoside-induced Ototoxicity by Regulated AAV Vector-mediated GDNF Gene Transfer Into the Cochlea. Mol Ther 2008, 16, 474-480.
  56. Kiyota, T.; Zhang, G.; Morrison, C.M., e al. AAV2/1 CD74 Gene Transfer Reduces beta-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer’s Disease. Mol Ther 2015, 23, 1712-1721.
  57. Gafni, Y.; Pelled, G.; Zilberman, Y., et al. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 2004, 9, 587-595.
  58. Sweeney, C.G.; Kearney, P.J.; Fagan, R.R., et al. Conditional, inducible gene silencing in dopamine neurons reveals a sex-specific role for Rit2 GTPase in acute cocaine response and striatal function. Neuropsychopharmacology 2020, 45, 384-393.
  59. de Solis, C.A.; Ho, A.; Holehonnur, R., et al. The Development of a Viral Mediated CRISPR/Cas9 System with Doxycycline Dependent gRNA Expression for Inducible In vitro and In vivo Genome Editing. Front Mol Neurosci 2016, 9, 70.
  60. Watakabe, A.; Takaji, M.; Kato, S., et al. Simultaneous visualization of extrinsic and intrinsic axon collaterals in Golgi-like detail for mouse corticothalamic and corticocortical cells: a double viral infection method. Front Neural Circuits 2014, 8, 110.
  61. Guilbaud, M.; Devaux, M.; Couzinie, C., et al. Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity. Hum Gene Ther 2019, 30, 802-813.
  62. Dong, B.; Nakai, H.; Xiao, W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010, 18, 87-92.
  63. Wu, Z.; Yang, H.; Colosi, P. Effect of genome size on AAV vector packaging. Mol Ther 2010, 18, 80-86.
  64. McKeage, K.; Deeks, E.D. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol 2010, 11, 217-222.
  65. Preshaw, P.M.; Novak, M.J.; Mellonig, J., et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol 2008, 79, 440-452.
  66. Chtarto, A.; Humbert-Claude, M.; Bockstael, O., et al. A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses. Mol Ther Methods Clin Dev 2016, 5, 16027.
  67. Weng, Y.; Fang, C.; Turesky, R.J., et al. Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res 2007, 67, 7825-7832.
  68. Dow, L.E.; Nasr, Z.; Saborowski, M., et al. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS One 2014, 9, e95236.
  69. Li, X.; Chuang, P.Y.; D’Agati, V.D., et al. Nephrin Preserves Podocyte Viability and Glomerular Structure and Function in Adult Kidneys. J Am Soc Nephrol 2015, 26, 2361-2377.
  70. Lu, Y.; Song, S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A 2009, 106, 17158-17162.
  71. Gregorevic, P.; Blankinship, M.J.; Allen, J.M., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004, 10, 828-834.
  72. Gao, G.; Lu, Y.; Calcedo, R., et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006, 13, 77-87.
  73. Pulicherla, N.; Shen, S.; Yadav, S., et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011, 19, 1070-1078.
  74. Wang, D.; Gao, G. Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. Mol Ther 2018, 26, 336-338.
  75. Tabebordbar, M.; Lagerborg, K.A.; Stanton, A., et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 2021, 184, 4919-4938 e4922.

Regular Issue Open Access Original Research
Volume 01
Issue 02
Received October 4, 2023
Accepted November 1, 2023
Published December 1, 2023